GSK, Arecor form vaccine stabilization pact

GlaxoSmithKline and Arecor have entered a collaboration to advance GSK's vaccines using Arecor's stabilization technology. Exact financial detail weren't disclosed, but the company's release stated Arecor would receive milestone payments and royalties.

"Arecor is pleased to work closely with one of the global leaders in vaccine products and technology," said Tom Saylor, CEO of Arecor, in a release. "The relationship with GSK offers Arecor the potential to apply its broad-ranging expertise in biomolecule stabilisation to specific projects with GSK."

Cambridge, U.K.-based Arecor has patented stabilization tools that combat biologics' degradation. GSK and Arecor believe this will extend the usability of GSK vaccines.

- read the Arecor release
- here's more from inPharm

Suggested Articles

After supply constraints hindered Shingrix's launch last year, GSK is planning to expand adjuvant manufacturing operations in Montana.

If a new draft law goes into effect, companies that make or sell fake vaccines could get fines of up to 30 times the value of the goods involved.

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.